#India #financial results #Mumbai #Piramal Pharmaceuticals #Q4 2025

Financial Performance of Piramal Pharma Limited for Q4 and FY2025

Piramal Pharma Limited recently announced its financial results for the fourth quarter (Q4) and the full fiscal year 2025 (FY2025). The announcement, made on May 15, 2025, demonstrated robust growth and a significant leap in operational performance, establishing the company as a noteworthy player in the pharmaceutical industry.

Key Financial Highlights

The consolidated revenue for Q4 FY2025 stood at ₹2,754 crores, reflecting an 8% year-over-year increase from ₹2,552 crores in Q4 FY2024. For the complete fiscal year, the revenues reached ₹9,151 crores, marking a 12% increase compared to ₹8,171 crores in FY2024.

• - CDMO Segment: The Contract Development and Manufacturing Organization (CDMO) segment contributed significantly to this growth, with revenues rising to ₹1,788 crores in Q4, an 8% increase from the previous year. The annual growth was even more impressive, up 15% to ₹5,447 crores for FY2025.
• - CHG Segment: The Complex Hospital Generics (CHG) segment reported a 6% quarterly increase and an 8% annual growth, showcasing steady demand in this competitive market.
• - ICH Segment: The India Consumer Health (ICH) segment achieved remarkable progress as well, with revenue reaching ₹1,093 crores for FY2025, reflecting an 11% annual rise.

Operating Performance

Piramal's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for the fourth quarter was ₹603 crores, also showing an 8% increase from ₹556 crores in Q4 FY2024. Remarkably, the EBITDA margin was held steady at 22% despite various market challenges. For the fiscal year, EBITDA surged to ₹1,580 crores—a 15% year-over-year improvement.

The company's operational efficiencies were mirrored in its net profit, which, before exceptional items, increased 16% to ₹154 crores for Q4. The total profit for FY2025 soared by 411% compared to the previous fiscal year.

Strategic Highlights

Chairperson Nandini Piramal emphasized the strategic initiatives undertaken during FY2025 to maintain the organization’s competitive edge:

• - The effective management of debt levels resulted in an improved net debt-to-EBITDA ratio of 2.7x.
• - The company has maintained its status of 'zero OAI' (no official action indicated) since 2011, indicating strong compliance and quality standards.
• - Substantial strides in sustainability efforts have led to improved ESG scores from SP Global and EcoVadis, illustrating the company's commitment to responsible business practices.

Significant product innovations and capacity expansions have positioned Piramal Pharma favorably in the competitive landscape, especially in the specialty pharmaceutical markets such as inhaled anesthesia, where it continues to lead the US market.

Growth Prospects

Looking ahead, Piramal Pharma has set ambitious goals for FY2030, targeting a revenue milestone of $2 billion and a sustainable EBITDA margin of 25%. With plans to enhance its innovation pipeline and expand its market reach, the company remains optimistic about its future prospects.

In summary, Piramal Pharma Limited's Q4 and FY2025 financial results underscore its operational excellence and strategic growth initiatives. As it stands poised for future growth, stakeholders can anticipate continued upward trends and significant contributions to the pharmaceutical sector.